Taipei Exchange
06:00:00 2024-05-14 pm EDT
5-day change
1st Jan Change
23.9
TWD
0.00%
-0.83%
-10.15%
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 13, 2021 at 03:10 pm EDT
Genovate Biotechnology Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was TWD 103.550 million compared to TWD 135.835 million a year ago. Operating income was TWD 6.682 million compared to TWD 19.302 million a year ago. Net income was TWD 8.653 million compared to TWD 18.579 million a year ago. Basic earnings per share was TWD 0.08 compared to TWD 0.18 a year ago.
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 28
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Genovate Biotechnology Co., Ltd. Announces Members of the Company's 5th Remuneration Committee
23-08-07
CI
Genovate Biotechnology Co., Ltd. Announces Cash Dividend, Payable August 7, 2023
23-06-15
CI
Genovate Biotechnology Co., Ltd. Approves Election of Directors
23-05-29
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Genovate Biotechnology Co., Ltd. and CSPC Pharmaceutical Group Limited Sign the Agreement on Technology Licensing and Co-Development of DBPR108 in Mainland China
23-04-28
CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Audit Committee Member and Convener of the Remuneration Committee, Effective April 10, 2023
23-04-06
CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Independent Director, Effective April 10, 2023
23-04-06
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-25
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-25
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-09
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-11
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-13
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-13
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-28
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-11
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
21-08-13
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-05-13
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-03-24
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
20-11-12
CI
Genovate Biotech Announces the Start of Its Clinical Trial (NCT04446416) for the Combination of FUS Plus Bevacizumab Therapy
20-09-11
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020
20-08-11
CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
20-05-13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
More about the company
1st Jan change
Capi.
-10.15% 81.34M +31.83% 595B -2.60% 367B +20.83% 334B +5.69% 289B +14.43% 239B +9.53% 211B -2.86% 203B +10.77% 171B +0.10% 163B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**
GENOVATE BIOTECHNOLOGY CO., LTD. 
